Hickory-Pecan Mix Allergy Shots (SCIT)
Hickory-pecan is the workhorse Juglandaceae SCIT preparation — a combined Carya extract blending pecan (C. illinoinensis) and shagbark hickory (C. ovata) to exploit near-complete intra-genus cross-reactivity, covering the full Carya genus in a single extract for South-Central and Mid-Atlantic patients.
Hickory-Pecan Mix Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to hickory-pecan mix — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of hickory-pecan mix allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of hickory-pecan mix immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of hickory-pecan mix extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for hickory-pecan mix allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing hickory-pecan mix extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription hickory-pecan mix immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat hickory-pecan mix allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Hickory-Pecan Mix?
The biology, taxonomy, and clinical fingerprint of Hickory-Pecan Mix — the foundation of how SCIT targets it.
Hickory-pecan mix combines catkin pollen from the two most clinically prominent Carya species — pecan (C. illinoinensis, dominant in the South-Central US) and shagbark hickory (C. ovata, most allergenic Carya in the Mid-Atlantic) — into a single SCIT preparation that exploits essentially complete intra-genus cross-reactivity.
- Scientific name
- Carya spp. (C. illinoinensis + C. ovata + regional species)
- Family
- JuglandaceaeWalnut family
- Type
- Deciduous tree pollen blend
- Native to
- Combined coverage: C. illinoinensis (South-Central US pecan belt) + C. ovata (Mid-Atlantic and eastern US)
- Allergen proteins
- NO IUIS-named pollen allergen for any Carya species as of May 2026 — the most significant evidence gap in US Juglandaceae allergenologyCuevas-Zuviría et al. (J Proteomics 2021) identified 17 IgE-binding proteins in pecan pollen — likely shared across Carya genus but not individually characterizedNamed Carya allergens at WHO/IUIS are ALL kernel (food) proteins from pecan (C. illinoinensis): Car i 1 (2S albumin), Car i 2 (vicilin), Car i 4 (11S legumin)CRITICAL: Hickory-pecan pollen SCIT does NOT treat Car i 1/2/4 kernel food allergy or pecan/hickory/walnut kernel anaphylaxis
- Particle size
- 43–53 μm (pecan); ~30–45 μm (shagbark hickory)
- Avoidance difficulty
- Nearly impossible
How Hickory-Pecan Mix Allergy Presents
Symptoms by body system — useful for distinguishing Hickory-Pecan Mix sensitivity from overlapping allergies and infections.
Respiratory (Pollen — Inhalant Allergy)
- Sneezing and profuse rhinorrhea during mid-April through May Carya pollen season across the South-Central and Mid-Atlantic US
- Nasal congestion on high-pollen days in TX, OK, LA, AR, MS, and the Mid-Atlantic (VA, MD, PA, DC)
- Itchy, swollen nasal passages during the 4–6 week Carya catkin release season — often overlapping with oak season
- Allergic asthma exacerbations in sensitized patients during peak Carya weeks
- Post-nasal drip and chronic cough from sustained hickory-pecan pollen exposure
Ocular
- Bilateral eye itching and watering during the April–May Carya season
- Conjunctival redness on high-pollen days — particularly in areas with both pecan orchards and native hickory canopy
- Morning eyelid puffiness from overnight pollen settling
- Photophobia and reduced visual comfort during peak Carya weeks
Dermal
- CRITICAL DISAMBIGUATION: Pecan and hickory kernel food allergy is driven by heat-stable storage proteins (Car i 1/2/4 from pecan; cross-reactive with hickory and walnut kernels) — these are NOT treated by hickory-pecan pollen SCIT. If you experience systemic reactions after eating pecans, hickory nuts, or walnuts, carry an epinephrine auto-injector regardless of SCIT status.
- Contact dermatitis from hickory or pecan tree sap or green hull handling
- Atopic dermatitis flares coinciding with Carya pollen season in susceptible patients
Systemic
- Fatigue and sleep disruption from spring Carya allergy in the South-Central and Mid-Atlantic US, amplified by concurrent oak and ash exposure
- Impaired outdoor activity during prime spring season — Carya season coincides with peak outdoor work in agricultural South-Central regions
- Anxiety around pecan and hickory kernel consumption if co-existing storage-protein food allergy is present
- Diagnostic confusion between the pollen allergy (treatable by SCIT) and the kernel food allergy (not treatable by SCIT) remains common and requires component testing
Hickory-pecan is the workhorse Juglandaceae mix in the South-Central and Mid-Atlantic — one extract to cover the entire Carya genus, because intra-genus cross-reactivity is essentially complete. The clinical magnitude is there (Hoffman's 27.8% in US children with rhinitis), but we have no Phase 3 trial and no named IUIS pollen allergen — this is the textbook example of family-level evidence carrying clinical practice.
When & Where Hickory-Pecan Mix Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: mid-April through May — Carya genus pollen release across the South-Central and Mid-Atlantic US· ~4–6 weeks; hickory pollen (Mid-Atlantic) often starts a week before pecan (South-Central) in many years; substantial overlap with oak season
US Exposure Map
9 high-intensity statesWhat Hickory-Pecan Mix Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Hickory-pecan cross-reactivity is built on the essentially complete intra-Carya pollen protein overlap — the scientific and clinical rationale for combining these species into one extract. Cross-genus Juglandaceae cross-reactivity with walnut (Juglans) is documented at the kernel level (storage-protein cross-reactivity) and inferred at the pollen level.
Within-Carya; essentially complete pollen cross-reactivity — this is why the mix works
Within-Carya; essentially complete; shagbark ranked most allergenic Carya species
Kernel storage-protein cross-reactivity (Car i 1/2/4, Jug r 1/2/4) — NOT addressed by pollen SCIT
Is SCIT Right for Your Hickory-Pecan Mix Allergy?
Answer five questions to assess whether hickory-pecan SCIT is appropriate for your South-Central or Mid-Atlantic spring allergy profile.
How severe are your spring symptoms during April–May Carya pollen season?
The Hickory-Pecan Mix SCIT Protocol
Hickory-pecan SCIT uses a non-standardized Carya combined extract — typically blending C. illinoinensis (pecan) and C. ovata (shagbark hickory), with some manufacturers adding C. tomentosa (mockernut) and C. cordiformis (bitternut). In southern Mix B/Mix C regional protocols, the hickory-pecan maintenance dose may be pushed to 1:50 w/v where Carya is the dominant spring allergen. Fall or winter build-up initiation is preferred to avoid active Carya season co-exposure.
Injections begin at 1:100,000 w/v and increase incrementally. South-Central patients should start in fall (September–November) to be at or near maintenance before mid-April pecan season. Mid-Atlantic patients targeting the shagbark season should similarly start in fall to avoid the April peak. Patients with confirmed kernel food allergy (Car i 1/2/4) must continue strict kernel avoidance and carry an epinephrine auto-injector throughout SCIT. Traditionally each injection was followed by a 30-minute observation period; with Curex, eligible patients self-administer the same escalation schedule at home, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand.
Ongoing maintenance at the target dose sustains full Carya genus-level tolerance. In regional southern Mix B/Mix C protocols where hickory-pecan is the dominant clinical allergen, some allergists push maintenance to 1:50 w/v for greater clinical effect — this is standard regional practice, not based on formal RCT data. Cross-protection to walnut (Juglans) at the pollen level is assumed but not formally characterized.
Lasting benefit of 7–12+ years expected with full course completion. SCIT discontinuation has no impact on kernel food allergy management — strict avoidance and epinephrine carry continue indefinitely for patients with Car i 1/2/4 sensitization.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Hickory-Pecan Mix SCIT
Hickory-pecan SCIT has no species-specific or combined-extract RCT. Efficacy is honestly characterized as extrapolated from the general Carya sensitization evidence base (Hoffman 1996, Bucholtz series) and the AAAAI Practice Parameter for allergen immunotherapy.
- Carya SPT positivity in US children with rhinitis28%Hoffman 1996 (cited Thermo Fisher t22): 27.8% SPT-positive in 209 US rhinitis patients
- Pecan/hickory reactivity in NYC tree-allergic patients27%Bucholtz et al. NYC series: 27.1% of 371 tree-allergic patients
- General inhalant SCIT efficacy for non-standardized tree pollen extracts55%Cox L et al., J Allergy Clin Immunol 2011 — AAAAI Practice Parameter general evidence framework
Hickory-pecan SCIT has no Phase 3 RCT and no formally named pollen allergens. The Hoffman 1996 and Bucholtz sensitization data establish that Carya genus pollen is a major aeroallergen affecting 27–28% of US rhinitis patients — a clinical magnitude justifying immunotherapy despite the evidence gaps. The combined hickory-pecan formulation exploits essentially complete intra-Carya cross-reactivity to provide full genus coverage in one extract, following the same efficiency rationale as birch-mix for Betula or oak-mix for Quercus.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Hickory-Pecan Mix SCIT Side Effects
Hickory-pecan SCIT side effects follow the standard inhalant SCIT profile. Fall/winter build-up initiation is strongly preferred for both South-Central (avoiding April pecan peak) and Mid-Atlantic (avoiding April shagbark peak) patients.
Local reactions
4 documentedSystemic reactions
4 documentedCRITICAL: Patients with confirmed pecan or hickory kernel food allergy (Car i 1/2/4-driven storage-protein allergy, or cross-reactive walnut Jug r 1/2/4) must continue strict kernel avoidance and carry an epinephrine auto-injector throughout and after hickory-pecan pollen SCIT. Pollen SCIT does not desensitize kernel storage-protein food allergy. This must be communicated clearly and repeatedly throughout the SCIT course.
SCIT vs Alternatives for Hickory-Pecan Mix
Patients with Carya genus sensitization — addressing hickory and pecan pollen inhalant allergy — have four main options. Kernel food allergy management is entirely separate and not addressed by any of these options.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Uncertain but standard practice — no Carya-specific RCT; Hoffman 1996 + Bucholtz data support clinical use | Uncertain — no hickory-pecan SLIT RCT; off-label Carya drops available | Low — Carya is widespread in South-Central and Mid-Atlantic landscape and agriculture | Moderate — antihistamines + nasal corticosteroids for mild-to-moderate symptoms |
| 5-yr cost | $3,500–$15,000 over 5 years | Varies by provider; sold as a general sublingual modality, not Curex's product | Low — HEPA, pollen masks, closed windows in April–May | $500–$2,000 over 5 years |
| Duration | 3–5 year course | 3–5 year course | Indefinite — no tolerance change | Indefinite — seasonal use |
| Convenience | At-home weekly self-injection with Curex; fall/winter start preferred; the first injection from each new vial or concentration supervised live in the Virtual Shot Room | Daily at-home — no clinic required | High inconvenience in prime spring outdoor season | High convenience |
| Safety | Excellent — serum is USP <797> sterile-compounded, the first injection from each new vial or concentration supervised live in the Virtual Shot Room, prescribed epinephrine auto-injector on hand, 30-min self-observation (pollen SCIT; kernel food allergy risks unchanged) | Favorable for pollen; does not affect kernel food allergy risk | Safe | Generally safe |
| Lasting effect | 7–12+ years after completion | Emerging data | None — symptoms return each April | None — must take every season |
SCITBest
SLIT
Avoidance
Medications
The hickory-pecan SCIT mix is the standard immunotherapy approach for the entire Carya genus — providing genus-level coverage from one extract for the 27% of US rhinitis patients who are Carya-sensitized across the South-Central and Mid-Atlantic regions. Curex now delivers that same SCIT as a weekly at-home injection at $129/month — the serum is sterile-compounded to USP <797>, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, and a prescribed epinephrine auto-injector is confirmed on hand — so you get full genus-level Carya coverage without the weekly clinic trip.
What Hickory-Pecan Mix SCIT Actually Costs
Hickory-pecan SCIT is covered by most major US insurers under standard allergy immunotherapy benefits when ordered by a board-certified allergist with documented sensitization. The combined preparation is typically billed as part of a multi-species regional tree mix (southern Mix B/Mix C). Pre-authorization should specify all Carya and Juglandaceae components in the extract and their clinical justification. Curex at-home IgE testing identifies specific hickory-pecan mix sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes allergist consult, prescription, serum, supplies, and Virtual Shot Room supervision for at-home allergy shots (SCIT).
See if you qualifyStop guessing about your hickory-pecan mix allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Hickory-Pecan Mix SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Intra-Carya pollen cross-reactivity is essentially complete — meaning patients sensitized to pecan pollen (C. illinoinensis) typically react equally to shagbark hickory (C. ovata), mockernut (C. tomentosa), and bitternut (C. cordiformis) pollen via shared genus-level pollen proteins. Because the same antigenic epitopes are present across all Carya species, a single combined Carya extract provides equivalent genus-wide immunotherapy without the additional extract volume, complexity, and cost of separate species-specific vials. This follows the same efficiency rationale as birch-mix (covering multiple Betula species) or oak-mix (covering Q. alba and Q. rubra) — combining species within a genus where cross-reactivity is functionally complete.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.